108 related articles for article (PubMed ID: 25639617)
1. Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib.
Silva E; Gatalica Z; Vranic S; Basu G; Reddy SK; Voss A
Breast J; 2015; 21(2):205-7. PubMed ID: 25639617
[No Abstract] [Full Text] [Related]
2. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
Hoshina D; Abe R; Yoshioka N; Saito N; Hata H; Fujita Y; Aoyagi S; Shimizu H
J Dermatol Sci; 2013 May; 70(2):116-22. PubMed ID: 23522954
[TBL] [Abstract][Full Text] [Related]
3. Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.
Ravi V; Sanford EM; Wang WL; Ross JS; Ramesh N; Futreal A; Patel S; Stephens PJ; Miller VA; Ali SM
J Natl Compr Canc Netw; 2016 May; 14(5):499-502. PubMed ID: 27160228
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.
Argyros O; Karampelas T; Varela A; Asvos X; Papakyriakou A; Agalou A; Beis D; Davos CH; Fokas D; Tamvakopoulos C
Oncotarget; 2017 Jun; 8(23):37250-37262. PubMed ID: 28422745
[TBL] [Abstract][Full Text] [Related]
6. Refractory cutaneous angiosarcoma successfully treated with sunitinib.
Lu HJ; Chen PC; Yen CC; Hsiao FC; Tzeng CH; Ma H; Shiau CY; Chao TC
Br J Dermatol; 2013 Jul; 169(1):204-6. PubMed ID: 23383874
[No Abstract] [Full Text] [Related]
7. Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.
Prenen H; Smeets D; Mazzone M; Lambrechts D; Sagaert X; Sciot R; Debiec-Rychter M
Oncotarget; 2015 Nov; 6(34):36418-25. PubMed ID: 26474454
[TBL] [Abstract][Full Text] [Related]
8. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
Tanaka Y; Shibata MA; Morimoto J; Otsuki Y
Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369
[TBL] [Abstract][Full Text] [Related]
10. Activity of sunitinib in extraskeletal myxoid chondrosarcoma.
Stacchiotti S; Pantaleo MA; Astolfi A; Dagrada GP; Negri T; Dei Tos AP; Indio V; Morosi C; Gronchi A; Colombo C; Conca E; Toffolatti L; Tazzari M; Crippa F; Maestro R; Pilotti S; Casali PG
Eur J Cancer; 2014 Jun; 50(9):1657-64. PubMed ID: 24703573
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
12. Angiosarcoma of the breast and vascular endothelial growth factor receptor.
Gennaro M; Valeri B; Casalini P; Carcangiu ML; Gronchi A; Conti AR; Agresti R; Greco M
Tumori; 2010; 96(6):930-5. PubMed ID: 21388054
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis as targeted breast cancer therapy.
Hayes DF; Miller K; Sledge G
Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib.
Heng DY; Kollmannsberger C
Recent Results Cancer Res; 2010; 184():71-82. PubMed ID: 20072832
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
17. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Stadler WM; Cao D; Vogelzang NJ; Ryan CW; Hoving K; Wright R; Karrison T; Vokes EE
Clin Cancer Res; 2004 May; 10(10):3365-70. PubMed ID: 15161690
[TBL] [Abstract][Full Text] [Related]
18. The potential role of sunitinib in gastrointestinal cancers other than GIST.
Grávalos C; Grande E; Gasent JM
Crit Rev Oncol Hematol; 2010 Oct; 76(1):36-43. PubMed ID: 20133148
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors.
Wragg JW; Heath VL; Bicknell R
Cancer Res; 2017 Feb; 77(4):1008-1020. PubMed ID: 28011623
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
